Colon cancer can act like a hungry engine. It burns sugar at a high rate to fuel fast growth. Now, scientists have mapped exactly where and how this sugar burning happens inside tumors. They also found a gene that helps keep this engine running.
This matters because colorectal cancer remains one of the most common cancers worldwide. It affects the colon or rectum and can be stubborn to treat once it spreads. Current therapies help many people, but tumors can resist treatment. Patients and caregivers often face a frustrating cycle: treatments work for a while, then the cancer adapts.
For years, doctors knew tumors use sugar differently than normal cells. But they did not fully understand which cells are doing the burning, where they sit inside the tumor, and what keeps them in that high-burn state. That gap makes it harder to design therapies that cut off the tumor’s fuel supply.
But here’s the twist. This study used advanced tools to zoom in on the tumor’s inner workings. It combined single-cell sequencing, which looks at individual cells, with spatial mapping, which shows where those cells are located. Together, they created a detailed picture of how sugar use varies across a tumor.
Think of a tumor like a busy city. Some neighborhoods hum with activity, while others are quieter. In this city, sugar burning is the energy source that keeps factories running. The researchers found a specific neighborhood of cancer cells that burns sugar at the highest rate. These cells act like a central power plant, sending signals that shape the surrounding environment.
The team identified three main types of malignant cells within colorectal tumors. One type, called Glycolysis-C1, stood out. These cells showed the highest glycolysis, the process cells use to break down sugar for energy. They clustered in the tumor core and along the border where tumor meets surrounding tissue. This location puts them in a prime spot to influence nearby cells.
The researchers also mapped how these cells communicate. Glycolysis-C1 cells released signals that act like instructions for other cells. One key signal is MIF, a molecule that binds to receptors on immune cells. By sending MIF, these cancer cells can reshape the immune environment around the tumor. This can make it harder for the body’s defenses to fight back.
To understand how these cells arise, the team traced their development over time. They found a path from low-sugar-burning cells to high-sugar-burning Glycolysis-C1 cells. This suggests tumors can shift their energy use as they grow and adapt.
This does not mean a new treatment is available yet.
The researchers then looked for genes that might control this high-sugar state. They combined genetic data from large studies with information from cancer databases. One gene kept rising to the top: NEK6. High levels of NEK6 in tumors were linked to worse outcomes and an immune environment that favors tumor growth.
To test NEK6’s role, the team ran lab experiments. They reduced NEK6 in colon cancer cells and watched what happened. The cells grew more slowly. Their sugar burning dropped. And they were less able to push immune cells toward a tumor-friendly state. These results point to NEK6 as a key regulator of the high-sugar engine.
What does this mean for patients right now? This research is still in the lab stage. It does not change how colorectal cancer is treated today. But it does suggest a new path for future therapies. If drugs can lower NEK6 activity or block the MIF-CD44 signaling hub, they might cut off the tumor’s fuel and weaken its hold on the immune system.
It is important to note the limits of this work. The study relied on lab models and cancer databases. Human tumors are complex, and what works in a dish may not work the same way in the body. Larger studies and clinical trials are needed to confirm whether targeting NEK6 is safe and effective.
Looking ahead, researchers will likely explore NEK6 inhibitors and other ways to disrupt the MIF-CD44 pathway. They will also study how to combine these approaches with existing treatments like chemotherapy or immunotherapy. The goal is to turn off the tumor’s power plant while helping the immune system do its job.
For now, patients with colorectal cancer should continue to follow their care plan and talk with their doctors about available options. If you are interested in new research, ask your care team about clinical trials in your area. Science moves step by step, and each finding brings us closer to smarter, more personalized treatments.